Neurocrine Biosciences Patents – Insights & Stats

Neurocrine Biosciences has a total of 1588 patents globally, out of which 623 have been granted. Of these 1588 patents, more than 50% patents are active. The United States of America is where Neurocrine Biosciences has filed the maximum number of patents, followed by Japan and Europe. Parallelly, United States of America seems to be the main focused R&D centre and also is the origin country of Neurocrine Biosciences.

Neurocrine Biosciences was founded in the year 1992. Neurocrine Biosciences is focused on the discovery and development of therapeutics for neuropsychiatric, neuro inflammatory, and neurodegenerative diseases and disorders. The Company is creating therapeutic interventions for the treatment of anxiety, depression, Alzheimer’s, insomnia, stroke, malignant brain tumours, multiple sclerosis, obesity, and diabetes. As of March 2023, Neurocrine Biosciences has a market cap of $9.72 Billion.

Do read about some of the most popular patents of Neurocrine Biosciences which have been covered by us in this article and also you can find Neurocrine Biosciences patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Neurocrine Biosciences patent portfolio.

How many patents does the founder and the CEO of Neurocrine Biosciences have?

The founders Errol De Souza has 11, Larry Bock has 15, Wylie Vale has 19 patents and CEO Kevin C. Gorman has 0 patents.

How many patents does Neurocrine Biosciences have?

Neurocrine Biosciences has a total of 1588 patents globally. These patents belong to 247 unique patent families. Out of 1588 patents, 798 patents are active.

How Many Patents did Neurocrine Biosciences File Every Year?

Neurocrine Biosciences Patent Filling Trend

Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.

Year of Patents Filing or GrantNeurocrine Biosciences Applications FiledNeurocrine Biosciences Patents Granted
20233
20224862
20216972
202012147
2019819
20187113
20178619
201612411
20156713
20143314
20133319
20122431
20111017

Which Neurocrine Biosciences Drug Patents are Expiring in the Next 10 Years?

The patent no. US10065952B2 which is expiring in Oct, 2036, describes treating hyperkinetic movement disorders, including symptoms of tardive dyskinesia, involves giving a pharmaceutically acceptable salt of (S)-2-amino-3-methyl-butyric acid in specific forms. This can be in amorphous or crystalline states. The process of making these forms and the resulting pharmaceutical compositions are also part of the treatment.

Given below is the list of few drugs patented by Neurocrine Biosciences accompanied by a patent relevant to the drug which will be available for generic drug manufacturing and usage within the next/upcoming 10 years for treatment of various diseases and disorders.

Drug NamePatent NumberPatent TitlePatent Expiration
IngrezzaUS10065952B2Valbenazine Salts And Polymorphs…Oct, 2036
OngentysUS8168793B2Nitrocatechol Derivatives As COMT…Apr, 2029

How many Neurocrine Biosciences patents are Alive/Dead?

Neurocrine Biosciences Patent Portfolio

How Many Patents did Neurocrine Biosciences File in Different Countries?

Neurocrine Biosciences Worldwide Patent Filling

Countries in which Neurocrine Biosciences Filed Patents

CountryPatent
United States Of America200
Japan108
Europe96
Australia81
China64
Mexico57
Canada57
Hong Kong (S.A.R.)53
Korea (South)51
United Kingdom42
Germany42
Israel39
Brazil37
Spain35
India35
Taiwan31
Austria29
Singapore28
South Africa26
Norway24
New Zealand23
Portugal23
Denmark23
Indonesia19
Viet Nam18
Argentina17
Malaysia17
Poland16
Russia16
Eurasia14
Philippines13
Chile12
Malta11
Slovenia9
Pakistan9
Croatia9
Hungary9
Peru8
Morocco8
Lithuania7
Serbia7
Uruguay4
Italy4
Jordan4
Turkey3
Cyprus3
Albania3
Africa4
Tunisia3
Iceland3
Colombia3
Panama2
Costa Rica2
Slovakia2
Bangladesh2
United Arab Emirates2
Saudi Arabia2
Montenegro1
Gulf Cooperation Council1
Czech Republic1
Former Yugoslav Republic of Macedonia1
Estonia1
Ecuador1
Mongolia1
Ukraine1

Where are Research Centres of Neurocrine Biosciences Patents Located?

R&D Centers of Neurocrine Biosciences

10 Best Neurocrine Biosciences Patents

WO2005040109A1 is the most popular patent in the Neurocrine Biosciences portfolio. It has received 262 citations so far from companies like Merck & Co, Xenon Pharmaceuticals and Sanofi.

Below is the list of 10 most cited patents of Neurocrine Biosciences:

Publication NumberCitation Count
WO2005040109A1262
WO2003031410A1177
WO2008058261A1158
WO2003094918A1148
WO2003068738A1118
US8039627B2108
US6399621B1107
WO2008070661A1100
WO2005007165A195
WO2009062087A192

How many inventions of other companies were rejected due to Neurocrine Biosciences patents?

The statistics below share strategic R&D insights. It tells the companies that were trying to protect inventions similar to Neurocrine Biosciences invention. They couldn’t because Neurocrine Biosciences had protected those before them.

Examiners at the USPTO referred 22 Neurocrine Biosciences patents in 51 rejections (35 USC § 102 or 35 USC § 103 types).

The top citing companies in the Neurocrine Biosciences patent portfolio are Spruce Biosciences, Auspex Pharmaceuticals and Abbvie.

List of the Companies whose Patents were rejected citing Neurocrine Biosciences –

CompanyNumber of Patent Applications that faced Rejection Citing Neurocrine Biosciences PatentsNumber of Rejections (102 & 103)
Spruce Biosciences23
Auspex Pharmaceuticals22
Abbvie28
Sequential Medicine22
Nihon Kohden11
Jagotec11
United States Secretary of Army11
Assia Chemical Industries11
Millennium Pharmaceuticals11
Addex Pharmaceuticals11

Count of 102 and 103 Type Rejections based on Neurocrine Biosciences Patents

Top Neurocrine Biosciences Patents used in Rejecting Most Patent Applications

Patent NumberCount of Rejected Applications
US8039627B24
US6485746B14
US20170020877A12
US7771632B22
US8765948B22
US9012436B22
US7034118B21
US6399621B11
US20050192286A11
US20040157851A11
US6750350B21
US20050176738A11
US7419983B21
US9649280B21
US20030091632A11

What Percentage of Neurocrine Biosciences US Patent Applications were Granted?

Neurocrine Biosciences (Excluding its subsidiaries) has filed 267 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 128 have been granted leading to a grant rate of 61.24%.

Below are the key stats of Neurocrine Biosciences patent prosecution at the USPTO.

Which Law Firms Filed Most US Patents for Neurocrine Biosciences?

Law FirmTotal ApplicationsSuccess Rate
Seed IP12579.17%
Fish & Richardson7955.71%
Global Patent Group1780.00%
Glaxosmithkline944.44%
C O Vp Ip Legal683.33%
Cooley Llp60.00%
Neurocrine Biosciences5100.00%
Karl R Hermanns3100.00%
Scully Scott Murphy & Presser3100.00%
Pfizer2100.00%

What are Neurocrine Biosciences key innovation segments?

What Technologies are Covered by Neurocrine Biosciences?

The chart below distributes patents filed by Neurocrine Biosciences in different countries on the basis of the technology protected in patents. It also represents the markets where Neurocrine Biosciences thinks it’s important to protect particular technology inventions.

R&D Focus: How has Neurocrine Biosciences search focus changed over the years?

EXCLUSIVE INSIGHTS COMING SOON!

Interested in knowing about the areas of innovation that are being protected by Neurocrine Biosciences?

Related Articles

Ufraction8 Patents – Insights & Stats (Updated 2024)

Ufraction8 has a total of 16 patents globally, out of which 7 have been granted. Of these 16 patents, more than 87% patents are active. Parallelly, United Kingdom seems to be the main focused R&D centre and also is the origin country of Ufraction8. Ufraction8 was founded in the year

Read More »

Aizant Patents – Insights & Stats (Updated 2024)

Aizant has a total of 64 patents globally, out of which 8 have been granted. Of these 64 patents, more than 45% patents are active. India is where Aizant has filed the maximum number of patents, followed by United States of America and Canada. Parallelly, India seems to be the

Read More »

Leave a Comment

Fill the form to get the details:

Our comprehensive report provides an in-depth look into the patent portfolio. The report includes a breakdown of the patent portfolio across various technologies, listing the patent along with brief summaries of each patent's technology.